Isomorphic Labs’ Series B financing is the second largest ever raised by a biotech startup. Like the largest one, Isomorphic is also opaque about its drug programs.
Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.